Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects
Sneve M, Figenschau Y, Jorde R
European journal of endocrinology · 136 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Helse Nord RHF
Según 1 financiador declarado.
Publicación
- Publicado
- 2008-12-01 · Eur J Endocrinol · vol. 159 · número 6 · págs. 675–684
- Editorial
- Oxford University Press
- Citado
- 201 citas · más que el 98% de estudios similares · 7.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 34 trabajos
- Acceso
- De pago
- Áreas de investigación
- Vitamin D Research Studies · Nutrition and Health Studies · Bone health and osteoporosis research
- Palabras clave
- vitamin D3, vitamin D supplementation, weight loss, obesity, overweight, 25-hydroxyvitamin D, parathyroid hormone, urinary calcium excretion, body fat distribution, waist-to-hip ratio, calcium supplementation, energy intake, body mass index
- MeSH
- humans, obesity, weight loss, cholecalciferol, vitamin d, body mass index, double-blind method, dietary supplements, adult, aged, middle aged, female, male, overweight, young adult
3 autores
- Monica Sneve🇳🇴 · autor de correspondenciaUniversity Hospital of North Norway
- Yngve Figenschau🇳🇴University Hospital of North Norway
- Rolf Jorde🇳🇴UiT The Arctic University of Norway
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
Investigate whether cholecalciferol supplementation leads to weight loss in overweight and obese adults.
Design
Randomized double blind clinical trial with 20,000 IU cholecalciferol twice a week, or 20,000 IU once a week plus placebo, or placebo twice a week, for 12 months. All subjects were given 500 mg calcium supplementation.
Methods
Four hundred and forty five healthy, overweight, and obese men and women (age 21-70 years, body mass index (BMI) 28.0-47.0 kg/m(2)). Body weight, fatness, and fat distribution parameters were measured by dual-energy X-ray absorptiometry and anthropometry, blood samples and 24-h urinary samples were collected.
Results
At baseline, there were no significant differences between the groups, but there was a significant inverse relation between serum 25-hydroxyvitamin D (25(OH)D) levels and BMI, and a significant positive association between calorie intake and BMI. Three hundred and thirty four subjects completed the study. During the study, there was no significant change in weight, waist-to-hip ratio (WHR) or percentage body fat in any of the groups, nor between them. Parathyroid hormone decreased and 25(OH)D increased significantly in both groups receiving cholecalciferol, and serum levels of 25(OH)D stabilized after 3 months. Serum calcium was unchanged in all groups. Urinary calcium excretion increased in all groups, but there was no significant difference between the groups. Weekly dosage of 20,000-40,000 IU cholecalciferol for 12 months was associated with a low risk of adverse effects, at least in overweight and obese adults living at latitude 70 degrees N.
Conclusion
Significant weight reduction in overweight and obese subjects is unlikely to occur with cholecalciferol supplementation.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.